StoryCommercial
LivaNova reports Q2 2025 results with double-digit revenue growth
LivaNova reported Q2 2025 results with double-digit reported and organic revenue growth and continued operating margin expansion, reflecting strong demand for both its neuromodulation and cardiac surgery product lines.